Voronoi, Inc. (KOSDAQ: 310210)

Market Cap	1.23T
Revenue (ttm)	n/a
Net Income (ttm)	-38.88B
Shares Out	17.95M
EPS (ttm)	-2,254.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	203,611
Open	70,900
Previous Close	70,800
Day's Range	68,000 - 71,400
52-Week Range	28,350 - 125,900
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 14, 2025

About Voronoi

Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company’s products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multipl...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 130
• Stock Exchange: KOSDAQ
• Ticker Symbol: 310210